New treatment option for young women with hormone-sensitive breast cancer

A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The findings from this trial were in women who had a form of early breast cancer that was sensitive to hormonal treatment. The combined results of the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (late breaking abstract #1) and published online in the New England Journal of Medicine. Read more here.